Retina Technologies Founder in the News!
Our President & COO, Alex Serafini, was recently interviewed by major scientific and media outlets for his work on the impact of SARS-CoV-2 (COVID-19 virus) on the nervous system. As the pandemic unfolded, Alex set aside time to work in a restricted biosafety level 3 facility to better understand why people who recovered from COVID-19 still suffered from debilitating conditions like headache, brain fog, and chronic pain. Alex presented data on mechanisms underlying long COVID-19-associated pain at Experimental Biology 2022, one of the largest basic biology and therapeutic conferences in the world.
Retina Technologies sees primary care as the initial target workflow for the OcuVue™ Platform. However, OcuVue™ can also be adapted for several relevant specialties, such as neurology (stroke, multiple sclerosis, and Alzheimer’s). In preliminary discussions, several neurologists have demonstrated excitement about a single device that can provide functional and imaging data. Expertise in the nervous system beyond the eye is yet another factor that sets our team apart from the competition!